Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 23, 2022 - Issue 3
Submit an article Journal homepage
260
Views
4
CrossRef citations to date
0
Altmetric
Key Paper Evaluation

The effect of dapagliflozin on ventricular arrhythmias, cardiac arrest, or sudden death in people with heart failure: a tick in another box for sodium-glucose cotransporter 2 inhibitors

Theocharis Koufakisa Division of Endocrinology and Metabolism and Diabetes Center, First Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA University Hospital, Thessaloniki, GreeceORCID Iconhttps://orcid.org/0000-0002-5853-1352
ORCID Icon,
George Giannakoulasb Cardiology Department, AHEPA University Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece
,
Pantelis Zebekakisa Division of Endocrinology and Metabolism and Diabetes Center, First Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA University Hospital, Thessaloniki, GreeceORCID Iconhttps://orcid.org/0000-0001-8821-406X
ORCID Icon &
Kalliopi Kotsaa Division of Endocrinology and Metabolism and Diabetes Center, First Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA University Hospital, Thessaloniki, GreeceCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-2376-740X
ORCID Icon
Pages 321-325 | Received 15 Sep 2021, Accepted 03 Nov 2021, Published online: 16 Nov 2021

References

  • Curtain JP, Docherty KF, Jhund PS, et al. Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF. Eur Heart J. 2021;42(36):3727–3738.
  • Park JJ. Epidemiology, pathophysiology, diagnosis and treatment of heart failure in diabetes. Diabetes Metab J. 2021;45:146–157.
  • Shen L, Jhund PS, Petrie MC, et al. Declining risk of sudden death in heart failure. N Engl J Med. 2017;377:41–51.
  • Tomaselli GF, Zipes DP. What causes sudden death in heart failure? Circ Res. 2004;95:754–763.
  • McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381:1995–2008.
  • Zannad F, Ferreira JP, and Pocock SJ, et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet. 2020;396:819–829.
  • Li HL, Lip GYH, Feng Q, et al. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis. Cardiovasc Diabetol. 2021;20:100.
  • Weiss JN, Nademanee K, Stevenson WG, et al. Ventricular arrhythmias in ischemic heart disease. Ann Intern Med. 1991;114:784–797.
  • Koufakis T, Mustafa OG, Ajjan RA, et al. The use of sodium-glucose co-transporter 2 inhibitors in the inpatient setting: is the risk worth taking? J Clin Pharm Ther. 2020;45:883–891.
  • Sayour AA, Korkmaz-Icöz S, Loganathan S, et al. Acute canagliflozin treatment protects against in vivo myocardial ischemia-reperfusion injury in non-diabetic male rats and enhances endothelium-dependent vasorelaxation. J Transl Med. 2019;17:127.
  • Azam MA, Chakraborty P, Si D, et al. Anti-arrhythmic and inotropic effects of empagliflozin following myocardial ischemia. Life Sci. 2021;276:119440.
  • Byrne NJ, Matsumura N, Maayah ZH, et al. Empagliflozin blunts worsening cardiac dysfunction associated with reduced NLRP3 (nucleotide-binding domain-like receptor protein 3) inflammasome activation in heart failure. Circ Heart Fail. 2020;13:e006277.
  • Philippaert K, Kalyaanamoorthy S, Fatehi M, et al. Cardiac late sodium channel current is a molecular target for the sodium/glucose cotransporter 2 inhibitor empagliflozin. Circulation. 2021;143:2188–2204.
  • Uthman L, Baartscheer A, Bleijlevens B, et al. Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+/H+ exchanger, lowering of cytosolic Na+ and vasodilation. Diabetologia. 2018;61:722–726.
  • Chung YJ, Park KC, Tokar S, et al. Off-target effects of SGLT2 blockers: empagliflozin does not inhibit Na+/H+ exchanger-1 or lower [Na+]i in the heart. Cardiovasc Res. 2020:cvaa323. doi: https://doi.org/10.1093/cvr/cvaa323.
  • Shimizu W, Kubota Y, and Hoshika Y, et al. Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial. Cardiovasc Diabetol 2020;19:148.
  • Bhatt DL, Szarek M, Steg PG, et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. 2021;384:117–128.
  • Koufakis T, Mustafa OG, Tsimihodimos V, et al. Insights into the results of sotagliflozin cardiovascular outcome trials: is dual inhibition the cherry on the cake of cardiorenal protection? Drugs. 2021;81:1365–1371.
  • Kosiborod M, Esterline R, Furtado RHM, et al. Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2021;9:586–594.
  • Koufakis T, Maltese G, Metallidis S, et al. Looking deeper into the findings of DARE-19: failure or an open door to future success? Pharmacol Res. 2021. DOI:https://doi.org/10.1016/j.phrs.2021.105872.
  • Tsimihodimos V, Filippas-Ntekouan S, Elisaf M. SGLT1 inhibition: pros and cons. Eur J Pharmacol. 2018;838:153–156.
  • Koufakis T, Papanas N, Dimitriadis G, et al. Interpreting the results of the VERTIS-CV trial: is this the end of the “class effect” perspective? J Diabetes. 2020;12:942–945.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.